You have full text access to this OnlineOpen article

Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial

  1. M. J. Kaviani1,
  2. M. R. Hashemi2,
  3. A. R. Kazemifar1,
  4. S. Roozitalab1,
  5. A.-A. Mostaghni3,
  6. S. Merat4,
  7. M. Alizadeh-Naini1,
  8. H. Yarmohammadi1

Article first published online: 16 JAN 2003

DOI: 10.1046/j.1365-2036.2003.01416.x

Issue

Alimentary Pharmacology & Therapeutics

Alimentary Pharmacology & Therapeutics

Volume 17, Issue 2, pages 211–216, January 2003

Additional Information

How to Cite

Kaviani, M. J., Hashemi, M. R., Kazemifar, A. R., Roozitalab, S., Mostaghni, A.-A., Merat, S., Alizadeh-Naini, M. and Yarmohammadi, H. (2003), Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Alimentary Pharmacology & Therapeutics, 17: 211–216. doi: 10.1046/j.1365-2036.2003.01416.x

Author Information

  1. 1

    Gastroenterohepatology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran;

  2. 2

    Bandar-Abbas University of Medical Sciences, Bandar-Abbas, Iran;

  3. 3

    Boushehr University of Medical Sciences, Boushehr, Iran;

  4. 4

    Digestive Diseases Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

*Correspondence to: Dr M. J. Kaviani, Gastroenterohepatology Research Center, Nemazee Hospital, Shiraz University of Medical Sciences, P.O. Box 71935-1311, Shiraz, Iran. E-mail: kavianim@sums.ac.ir

Publication History

  1. Issue published online: 16 JAN 2003
  2. Article first published online: 16 JAN 2003
  3. Accepted for publication 29 September 2002

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (65K)

Summary

Background : Endoscopic therapies and continuous intravenous omeprazole can decrease the morbidity and duration of hospital stay of patients with high-risk peptic ulcer.

Aim : To evaluate the role of oral omeprazole in high-risk bleeders.

Methods : After injection therapy of 160 patients with high-risk peptic ulcer, 80 received oral omeprazole and 80 received placebo, and all were followed up.

Results : One hundred and forty-nine patients (71 omeprazole and 78 placebo) completed the study. Eleven patients were excluded from the study. Thirty-seven (25%) patients had gastric ulcer and 112 (75%) had duodenal ulcer. Fifty-seven (38%) ulcers showed visible vessels, 80 (54%) showed oozing of blood and 12 (8%) showed a spurting artery. Only one patient died (placebo group). The mean hospital stays were 62.8 ± 28.6 h and 75 ± 39 h in the omeprazole and placebo groups, respectively (P = 0.032). The mean amounts of blood transfused were 1.13 ± 1.36 and 1.68 ± 1.68 bags in the omeprazole and placebo groups, respectively (P = 0.029). The re-bleeding rate was lower in the omeprazole group than in the placebo group (12 vs. 26, respectively; P = 0.022).

Conclusion : Oral omeprazole is effective in decreasing the hospital stay, re-bleeding rate and the need for blood transfusion in high-risk ulcer bleeders treated with endoscopic injection therapy.

View Full Article (HTML) Get PDF (65K)